

Efavirenz/lamivudine/tenofovir  
disoproxil fumarate  
600mg/300mg/300mg tablets  
(Desano Pharmaceuticals Private  
Ltd), HA764

WHOPAR Part 5

March 2023

## **LABELLING**

## **PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

HDPE bottle

### **1. Name of the medicinal product**

[HA764 trade name] \*

Efavirenz/lamivudine/tenofovir disoproxil fumarate 600mg/300mg/300mg tablets

### **2. List of excipients**

Each tablet contains about 225.64 mg of lactose monohydrate and 43mg (1.87mmol) of sodium.

### **3. Pharmaceutical form and contents**

30 Tablets

90 Tablets

### **4. Method and route of administration**

Oral use

Read the patient information leaflet before use.

### **5. Special warning that the medicinal product must be stored out of the reach and sight of children**

Keep this medicine out of the sight and reach of children.

### **6. Other special warning(s), if necessary**

### **7. Expiry date**

EXP {MM/YYYY}

### **8. Special storage conditions**

Do not store above 30°C. Protect from light and moisture. Avoid excursions above 30°C.

### **9. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate**

### **10. Name and address of the supplier**

Desano Pharmaceuticals Private Limited

No. 77D, KIADB Industrial Area,

---

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Efavirenz/lamivudine/tenofovir  
disoproxil fumarate  
600mg/300mg/300mg tablets  
(Desano Pharmaceuticals Private  
Ltd), HA764

WHOPAR Part 5

March 2023

Jigani, Bengaluru,  
Karnataka- 560105,  
India

**11. WHO Reference Number (Prequalification Programme)**

HA764

**12. Manufacturer's batch number**

<Batch> <Lot> {number}

**13. (Advice on) General classification for supply**

Medicinal product subject to medical prescription.

**14. Instructions on use**